{"id":136941,"date":"2022-11-17T06:49:15","date_gmt":"2022-11-17T11:49:15","guid":{"rendered":"https:\/\/44.250.171.167\/?p=136941"},"modified":"2022-11-17T06:49:16","modified_gmt":"2022-11-17T11:49:16","slug":"jb-chemicals-pharmaceuticals-limited-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/jb-chemicals-pharmaceuticals-limited-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"JB Chemicals &#038; Pharmaceuticals Limited Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from JB Chemicals &amp; Pharmaceuticals Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/JBCHEPHARM\/\">JBCHEPHARM<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>[00:06:28] JBCHEPHARM said that in domestic markets it seeks to make its key brands stronger with a focus on building brand franchise in terms of market share and higher prescriptions. The company expects its domestic business to continue to outperform the market growth.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:12:53] Rahul Jeewani of IIFL Securities asked that in Sporlac, if the liquid probiotics is launched in the domestic market. Nikhil Chopra CEO said the company has launched a couple of formulations, a sachet version in the form of Sporlac GG. One or two more versions of Sporlac will be launched in the field of gastroenterology and women healthcare.<\/li>\n<\/ul>\n<ul>\n<li>[00:16:30] Rahul Jeewani of IIFL Securities also asked that given the strong growth in Azmarda, if the high base will become a headwind going into next year for Azmarda growth. Kunal Khanna President said that given the overall potential, even if there is some price erosion, volumes will be able to neutralize a good part of price erosion. And from a margin standpoint, the company will still be at a better position despite the price erosion, due to local sourcing options.<\/li>\n<\/ul>\n<ul>\n<li>[00:18:10] Rahul Jeewani of IIFL Securities asked about the growth in the CMO business going forward. Nikhil Chopra CEO said that in CMO business, what the company scored a century in 1Q, same happened in 2Q. JBCHEPHARM is placed in a sweet spot in terms of order book for 3Q and 4Q. CMO is being looked at from a long term perspective.<\/li>\n<\/ul>\n<ul>\n<li>[00:19:38] Rahul Jeewani of IIFL Securities also asked if there were any new clients in the CMO business and any new product launches. Nikhil Chopra CEO replied that with existing partners, JBCHEPHARM has added a couple of products. However, no new partners were added.<\/li>\n<\/ul>\n<ul>\n<li>[00:20:21] Rashmi Sancheti from Dolat Capital enquired that on the strong order book, if the company will upgrade its guidance of CMO for the entire year from 15%. Nikhil Chopra CEO said that growth will be higher vs. what the company has guided.<\/li>\n<\/ul>\n<ul>\n<li>[00:23:15] Abdulkader Puranwala of Elara asked about the performance of the base brand of Cilacar and Rantac and what\u2019s driving its growth. Nikhil Chopra CEO replied that Cilacar, Nicardia grew at mid teens and it was in line with what was planned.<\/li>\n<\/ul>\n<ul>\n<li>[00:23:25] Abdulkader Puranwala of Elara also asked about MR productivity considering a bit of MR additions post the previous acquisitions. Nikhil Chopra CEO said that by the end of FY23, MR productivity should be INR4 -6.5 lakh.<\/li>\n<\/ul>\n<ul>\n<li>[00:25:40] Abdulkader Puranwala of Elara enquired that on the quarterly run rate of INR110 crores in CDMO, what\u2019s the capacity that\u2019s underutilized. Nikhil Chopra CEO answered that from a capacity standpoint, JBCHEPHARM can go up almost 70-80% growth than what\u2019s currently manufactured.<\/li>\n<\/ul>\n<ul>\n<li>[00:28:15] Sriraam Rathi with BNP Paribas asked about the constant currency growth in exports business in 2Q23 and which markets did better. Lakshay Kataria CFO said that JBCHEPHARM saw some gains, maybe about 5-6 points being shaved off on currency gains and balance largely coming from the volume side.<\/li>\n<\/ul>\n<ul>\n<li>[00:35:58] Shrikant Akolkar from AMSEC enquired about the opportunity size for the IVF business in India. Kunal Khanna President answered that the IVF overall it runs into close to INR1,200-1,400 crore plus.<\/li>\n<\/ul>\n<ul>\n<li>[00:38:09] Cyndrella Carvalho from JM Financial asked about the outlook domestically, in terms of seasonality in the overall portfolio. Nikhil Chopra CEO replied that 4Q will be a bit soft but 3Q will be in line with the current performance.<\/li>\n<\/ul>\n<ul>\n<li>[00:39:11] \u00a0Cyndrella Carvalho from JM Financial asked about topline growth over a 2-3 years time. Nikhil Chopra CEO said the aspiration is to grow mid-teens top line and profit should grow better than the top line. So 14-16% top line, 16-18% bottom line.<\/li>\n<\/ul>\n<ul>\n<li>[00:46:28] Sonal Gupta from L&amp;T Mutual asked about the MR headcount number. Kunal Khanna President said the actual frontline sales force is 2,100; 1,600 for JB, and around 300 for Sanzyme and 200 for Azmarda.<\/li>\n<\/ul>\n<ul>\n<li>[00:53:49] Rajat Setiya of iThought PMS asked about the domestic business numbers without acquisitions. Kunal Khanna President said that the contribution of organic versus inorganic acquisitions, the acquired portfolio runs into close to INR82-84 crores.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from JB Chemicals &amp; Pharmaceuticals Limited (JBCHEPHARM) Q2 FY23 Earnings Concall Management Update: [00:06:28] JBCHEPHARM said that in domestic markets it seeks to make its key brands stronger with a focus on building brand franchise in terms of market share and higher prescriptions. The company expects its domestic business to continue to outperform [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"JB Chemicals & Pharmaceuticals Limited Q2 FY23 Earnings Conference Call Insights #JBCHEPHARM #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[8519,10169,1115],"class_list":["post-136941","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-chemicals","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":132625,"url":"https:\/\/alphastreet.com\/india\/jb-chemicals-pharmaceuticals-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":136941,"position":0},"title":"JB Chemicals &#038; Pharmaceuticals Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 8, 2022","format":false,"excerpt":"Key highlights from JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Q1 FY23 Earnings Concall Q&A Highlights: Rahul Jeewani from IIFL Securities asked about the drivers of growth on the CMO business in 1Q23. Nikhil Chopra CEO replied that overall, the company saw demand coming across all markets outside India. The demand\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":137917,"url":"https:\/\/alphastreet.com\/india\/jb-chemicals-pharmaceuticals-limited-jbchepharm-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":136941,"position":1},"title":"JB Chemicals &amp; Pharmaceuticals Limited (JBCHEPHARM) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"November 14, 2022","format":false,"excerpt":"JB Chemicals & Pharmaceuticals Limited\u00a0(NSE:JBCHEPHARM) Q2\u00a0FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Jason D'Souza\u00a0--\u00a0Vice President of Investor Relations Nikhil Chopra\u00a0--\u00a0Chief Executive Officer, Whole-Time Director Lakshay Kataria\u00a0--\u00a0Chief Financial Officer Kunal Khanna\u00a0--\u00a0President of Operations Analysts: Rahul Jeewani\u00a0--\u00a0IIFL Securities Limited -- Analyst Rashmi Sancheti\u00a0--\u00a0Dolat Capital -- Analyst Abdulkader Puranwala\u00a0--\u00a0Elara -- Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":142855,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-j-b-chemicals-pharmaceuticals-limited-for-q3-fy23\/","url_meta":{"origin":136941,"position":2},"title":"Earnings Summary Of J.B. Chemicals &#038; Pharmaceuticals Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 27, 2023","format":false,"excerpt":"J.B. Chemicals & Pharmaceuticals (NSE: JBCHEPHARM) has a diversified product portfolio that covers various therapeutic areas such as cardiology, dermatology, gastroenterology, neurology, and diabetology. The company's major brands include Metrogyl, Rantac, Nicardia, Cilacar, and Chericof. In addition to its prescription drug business, J.B. Chemicals & Pharmaceuticals also has a significant\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-32.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-32.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-32.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-32.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-32.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-32.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":127669,"url":"https:\/\/alphastreet.com\/india\/jb-chemicals-pharmaceuticals-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":136941,"position":3},"title":"JB Chemicals &#038; Pharmaceuticals Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 17, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=HiVTF6vv9q0 Key highlights from JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Q3 FY22 Earnings Concall Management Update: The company outperformed the sector with a growth of 27% versus market growth of 10% in 3Q22. Company\u2019s new product introductions are performing well in the market, considering that its contribution is now close\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":137010,"url":"https:\/\/alphastreet.com\/india\/iol-chemicals-and-pharmaceuticals-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":136941,"position":4},"title":"IOL Chemicals and Pharmaceuticals Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 21, 2022","format":false,"excerpt":"Key highlights from IOL Chemicals and Pharmaceuticals Limited (IOLCP) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:26] Venkat of 3Sigma Financials asked about the growth numbers for 3Q23 and FY24. Sanjay Chaturvedi CEO said that in FY23, IOLCP is going to show some muted growth in the single-digits, but in FY24,\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172949,"url":"https:\/\/alphastreet.com\/india\/j-b-chemicals-q2-fy26-earnings-results\/","url_meta":{"origin":136941,"position":5},"title":"J B Chemicals Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 9, 2025","format":false,"excerpt":"J B Chemicals & Pharmaceuticals Ltd, established in 1976 and one of India\u2019s leading pharmaceutical companies, is an integrated publicly listed organization focused on supplying affordable, quality products in India and globally, trusted by healthcare professionals worldwide. Financial Highlights: Revenues increased 8.39% year-on-year to \u20b91,085 crore from \u20b91,001 crore. Total\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/JB.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/JB.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/JB.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/JB.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/JB.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/JB.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=136941"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136941\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=136941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=136941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=136941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}